This study evaluated the performance of the newly developed and commercially available SensiScreen® EGFR Liquid kit for detection of the clinically relevant EGFR mutations in cfDNA from NSCLC patients—(c.2369C>T (p.T790M), Exon 19 deletions, c.2573T>G & c.2573_2574TG>GT (p.L858R)) -, accounting cumulatively more than 90% of the mutations that can hyper activate EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.